[Endocarditis in hemodialysis and prognosis].
de Lorenzo
A
A
Bernis
C
C
Diego
G
G
Sánchez Tomero
J A
JA
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000209:etiology; D002408:Catheters, Indwelling / Q000009:adverse effects*; D048909:Diabetes Complications / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D015299:Discitis / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D004697:Endocarditis, Bacterial / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology; D005334:Fever / Q000209:etiology; D006350:Heart Valve Prosthesis; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000150:complications; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008159:Lumbar Vertebrae; D016106:Methicillin Resistance; D011379:Prognosis; D006435:Renal Dialysis; D012293:Rifampin / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin; D012293:Rifampin